Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. AtoS SE
  6. Summary
    ATO   FR0000051732

ATOS SE

(ATO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/08/2021 06/09/2021 06/10/2021 06/11/2021 06/14/2021 Date
53.46(c) 53.2(c) 53.78(c) 54.5(c) 54.42(c) Last
464 961 568 524 496 316 613 879 525 994 Volume
+0.15% -0.49% +1.09% +1.34% -0.15% Change
More quotes
Financials
Sales 2021 11 349 M 13 755 M 13 755 M
Net income 2021 448 M 543 M 543 M
Net Debt 2021 21,4 M 26,0 M 26,0 M
P/E ratio 2021 13,4x
Yield 2021 2,01%
Sales 2022 11 646 M 14 115 M 14 115 M
Net income 2022 598 M 725 M 725 M
Net cash position 2022 546 M 662 M 662 M
P/E ratio 2022 10,1x
Yield 2022 2,52%
Capitalization 5 942 M 7 206 M 7 202 M
EV / Sales 2021 0,53x
EV / Sales 2022 0,46x
Nbr of Employees 104 430
Free-Float 86,3%
More Financials
Company
AtoS SE is one of the world leaders in IT services. The group's activity is organized around three sectors: - outsourcing services and consulting services; - system integration; - supply of transaction services: electronic payment transaction processing, remote payment management, development of payment solutions, etc. The group also develops an externalization of operating processes activity. Net sales break... 
Sector
IT Services & Consulting
Calendar
07/26Presentation
More about the company
Ratings of AtoS SE
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ATOS SE
06/11ATOSSA THERAPEUTICSá : Receives Swedish Regulatory Approval for Phase 2 Study of..
MT
06/10ATOSá : launches ‘Engaged Employee Experience' to support organizations ta..
GL
06/09UPDATE : Atossa Therapeutics' Phase 2 Endoxifen Breast Cancer Study Meets Primar..
MT
06/09ATOSSA THERAPEUTICS'á : Phase 2 Endoxifen Breast Cancer Study Meets Primary, Sec..
MT
06/09ATOSá : Joins EU Project AI4Cities
MT
06/09ATOSá : joins AI4Cities, the European project to accelerate the transition of ci..
GL
06/07ATOSSA THERAPEUTICSá : Shares Jump 35% Ahead of Data on Endoxifen in Breast Canc..
MT
06/03Atos Completes Acquisition Of Processia
MT
06/03ATOSá : completes the acquisition of digital manufacturing specialist Processia
GL
06/03ATOSá : Signs Five-Year Partnership With Huma
MT
06/03ATOSá : French Financial Markets Watchdog Denies Claims of Shareholder Building ..
MT
06/03ATOSá : and Huma enter into five-year partnership to improve healthcare and rese..
GL
06/02ATOSá : Launches New Offering To Help Companies Achieve Net-Zero Emissions
MT
06/02ATOSá : creates faster path to net zero with market-first end-to-end portfolio a..
GL
06/01ATOSá : Delivers Defense System SICS To French Army
MT
More news
News in other languages on ATOS SE
06/10ATOSá : lance ź Engaged Employee Experience ╗ pour aider les entreprises face au..
06/09ATOSá : rejoint AI4Cities, le projet européen visant à accélérer la transition d..
06/09ATOSá : participation au projet AI4Cities
06/09ATOSá : rejoint AI4Cities, le projet européen visant à accélérer la transition d..
06/07STOCK MARKET PARIS : Paris termine en petite hausse
More news
Stock Trading Strategies
ATOS SE - 2020
Close to a key resistance level
BUY
More Stock Trading Analysis
Chart ATOS SE
Duration : Period :
AtoS SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATOS SE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 72,09 €
Last Close Price 54,42 €
Spread / Highest target 71,6%
Spread / Average Target 32,5%
Spread / Lowest Target 4,74%
EPS Revisions
Managers and Directors
NameTitle
╔lie Girard Chief Executive Officer & Director
Uwe Stelter Chief Financial Officer
Bertrand Marc Andrew Meunier Non-Executive Chairman
Eric Grall Chief Operating Officer & Head-Manufacturing
Sophie Proust Group Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
ATOS SE-27.12%7 199
ACCENTURE PLC9.21%181 337
TATA CONSULTANCY SERVICES LTD.14.36%165 367
INTERNATIONAL BUSINESS MACHINES CORPORATION20.18%135 172
AUTOMATIC DATA PROCESSING, INC.13.31%84 955
INFOSYS LIMITED15.22%83 888